Syndax announces $200M public offering of common stock at $18.50/share

Syndax Pharmaceuticals Inc

Issued 10,810,810 shares at $18.50; gross proceeds ~$200M ($230M with overallotment).
Underwriters: Goldman Sachs, J.P. Morgan, Cowen and Company; deal expected to close Dec. 19, 2023.
Lock-up agreement: company, directors, officers, certain stockholders restricted for 60 days.
Offering made under existing S-3 shelf registration (File 333-254661).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $200.0 million (effective 2023-12-14).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters
Value: approximately $200.0 million
Effective: 2023-12-14

Exact text from the filing

On December 14, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 10,810,810 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a price to the public of $18.50 per share (the “ Offering ”).

View on SEC.gov

Browse all material agreements →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001193125-23-296814

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.